62908-83-2

Basic information

• Product Name: 3-Methyl-5-nitro-1H-pyrazolo[3,4-b]pyridine ,97%
• Synonyms: 3-Methyl-5-nitro-1H-pyrazolo[3,4-b]pyridine ,97%;3-Methyl-5-nitro-1H-pyrazolo[3,4-b]pyridine;1H-Pyrazolo[3,4-b]pyridine, 3-Methyl-5-nitro-;3-methyl-5-nitro-2H-pyrazolo[3,4-b]pyridine
• CAS NO: 62908-83-2
• Molecular Formula: C₇H₆N₄O₂
• Molecular Weight: 178.15
• Mol File: 62908-83-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 188-190℃
• Boiling Point: 243℃
• Flash Point: 101℃
• Appearance: /
• Density: 1.66
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.722
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Methyl-5-nitro-1H-pyrazolo[3,4-b]pyridine ,97%(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-5-nitro-1H-pyrazolo[3,4-b]pyridine ,97%(62908-83-2)
• EPA Substance Registry System: 3-Methyl-5-nitro-1H-pyrazolo[3,4-b]pyridine ,97%(62908-83-2)

Safety Data

• Hazardous Substances Data: 62908-83-2(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C7H6N4O2/c1-4-6-2-5(11(12)13)3-8-7(6)10-9-4/h2-3H,1H3,(H,8,9,10)

Upstream product

• 55676-21-6 3-acetyl-2-chloropyridine 
• 14188-94-4 3-acetylpyridine N-oxide 
• 350-03-8 methyl-3-pyridylketone 
• 34461-00-2 nitromalondialdehyde sodium salt 
• 31230-17-8 3-amino-5-methylpyrazole 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 

Downstream Products

• 1401732-56-6 1-(4-methoxybenzyl)-3-methyl-5-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazolo[3,4-b]pyridine 
• 1401731-60-9 3-methyl-5-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazolo[3,4-b]pyridine 
• 1186607-49-7 2,6-difluoro-3-(3-fluoropropylsulfonamido)-N-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)benzamide 
• 1401732-49-7 4-(6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)morpholine 
• 1401732-48-6 6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-N-(1-methyl-piperidin-4-yl)pyridin-2-amine 
• 1401732-47-5 5-(6-chloropyridin-2-yl)-1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1401731-38-1 1-methyl-N-(3-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)phenyl)piperidin-4-amine 
• 1401732-46-4 N-(3-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)phenyl)-1-methylpiperidin-4-amine 
• 1401732-45-3 5-(3-chlorophenyl)-1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1401731-36-9 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1401732-44-2 1-(3-((6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1401732-42-0 5-(6-(indolin-1-yl)pyrazin-2-yl)-1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1401732-41-9 N-(1-isopropylpiperidin-4-yl)-6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-amine 
• 1401732-39-5 4-(6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)piperazin-2-one 

Relevant articles and documents

SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3,4-B] PYRIDINE AND PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson?s disease, Alzheimer?s disease, Down?s Syndrome, Huntington?s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated there with using compounds and pharmaceutical compositions including the compounds.

PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

NITROAZINES. 20. SIMPLE SYNTHESES OF NITROPYRAZOLOPYRIDINES FROM ALIPHATIC NITROSYNTHONS AND AMINOPYRAZOLES

Two variants of a synthesis for nitropyrazolopyridines from aminopyrazoles and two- or three-carbon nitrosynthons are examined.